BT474 human breast carcinomas fragments were implanted subcutaneously in theright flank of the mice. Mice were divided into 4 treatment groups (N=8/group), as follows: trastuzumab-Compound (la) conjugate (5 mg/kg, iv, qd x 1); rituximab-Compound (la) conjugate (5 mg/kg, iv, qd x 1); pertuzumab-Compound (la) conjugate (5 mg/kg, iv, qd x 1).

Mice were orthotopically implanted with 1x10⁷ HCC1569 human breast cancer cells suspended in amixture of Matrigel and culture media in the inguinal fat pad. Following group allocation, mice were treated with a single 10 ml/kg lateral tail vein injection of a Pertuzumab-Compound (la) conjugate at 3 mg/kg.

Mice were orthotopically implanted with 1x10⁷ HCC1569 human breast cancer cells suspended in amixture of Matrigel and culture media in the inguinal fat pad. Following group allocation, mice were treated with a single 10 ml/kg lateral tail vein injection of a Pertuzumab-Compound (la) conjugate at 10 mg/kg.

The cells, at a predetermined concentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5% CO₂, serial dilutions of each test article (TA) were added to the cells. Cells were incubated with test articles for 72 hours. and viability was detected with CellTiter-Gloreagent.

Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.

Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.